AZD5363

Catalog No.S8019

AZD5363 Chemical Structure

Molecular Weight(MW): 428.92

AZD5363 potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2.

Size Price Stock Quantity  
In DMSO USD 235 In stock
USD 147 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • G-H. Analysis of cells treated with AZD5363 (500 nM) for 24 hrs. G.Western analysis of whole cell lysates. H. Cells labeled with Annexin V-FITC for 6h were imaged. Individual points are average for replicates assessed in duplicate. Midlines are the average ± S.D. Student’s T-test.

    Cancer Res, 2016, 76(16):4752-64.. AZD5363 purchased from Selleck.

    Inhibition of PI3K and Akt by LY294002 and AZD5363 was confirmed by analyzing expression and activation status of the ribosomal protein S6 by Western blot analysis of PC-3 clone #14 cells treated with 0.5 or 5 uM AZD5363 (AZD) and 10 uM LY294002 (LY). Tubulin was used as a loading control.

    Cell Commun Signal 2014 12(1), 61. AZD5363 purchased from Selleck.

  • (A) 239 cells stably expressing Flag-IL-17RA (293-IL-17RA cell line) were treated with 2 μM AZD5363 (a pan-Akt inhibitor) and/or 50 ng/ml insulin for the indicated time periods; Western blot analysis was performed for the indicated proteins; exogenous, IL-17RA transfected into 293 cells; endogenous, endogenous IL-17RA expressed in 293 cells.

    Oncotarget, 2016, 7(12):13651-66. AZD5363 purchased from Selleck.

    LNCaP, LNCaP95, VCaP and 22Rv1 cells were transfected with control or pooled siRNA for AKT 1–3 isoforms for 36 hours. Cells were then further treated with 5 uM AZD5363 (B) for another 18 hours. Protein lysates were immunoblotted with AR (N-20), AR-V7, Pan-AKT, p-AKT(ser473) and β-Actin antibodies. Results were repeated in more than three independent experiments.

    PLoS One 2014 9(10), e108780. AZD5363 purchased from Selleck.

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description AZD5363 potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2.
Features Moderate preclinical tolerability, and PD characteristics of an AKT inhibitor. Distinct profile from other AKT inhibitors in clinical development.
Targets
Akt1 [1]
(Cell-free assay)
Akt2 [1]
(Cell-free assay)
Akt3 [1]
(Cell-free assay)
ROCK2 [1]
(Cell-free assay)
3 nM 8 nM 8 nM 56 nM
In vitro

AZD5363 is a potent Akt inhibitor with IC50 of 3 nM, 8 nM and 8 nM for Akt1, Akt2 and Akt3, respectively. [1] AZD5363 inhibits phosphorylation of AKT substrates in cells with a potency of approximately 0.3 to 0.8 μM. AZD5363 inhibits the proliferation of 41 of 182 solid and hematologic tumor cell lines with a potency of < 3 μM. [2] Activating mutations in PIK3CA, loss or inactivation of tumor suppressor PTEN, or HER2 amplification all are significantly predictive of responsiveness to AZD5363. Additionally, correlation is also seen between the RAS mutation status of cell lines and resistance to AZD5363. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 Mo\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXiyNFAhdk1? MUO2JIQ> MXjpcoNz\WG|ZXSg[JJ2\yC|ZX7zbZRqfmm2eTDv[kA1NU:KVDDhcoQh\nWudnXzeJJidnR? NU[ybIg2OjZ|NUGzNlM>
ZR75 M4nDXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7yNVAxKG6P M{nTO|Yh\A>? NVfQO29XcW6lcnXhd4VlKGS{dXegd4Vve2m2aY\peJkhd2ZiND3PTHQh[W6mIH\1cJZme3S{YX70 NYn0N5V6OjZ|NUGzNlM>
T74D MmT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkH3NVAxKG6P MXy2JIQ> NITvW|RqdmO{ZXHz[YQh\HK3ZzDz[Y5{cXSrdnn0fUBw\iB2LV;IWEBidmRiZoXseoV{fHKjboS= MVeyOlM2OTN{Mx?=
1%MCF7 NWDHNoNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXO0NFAhdk1? NFHE[4Q3KGR? NX:1WWVjcW6lcnXhd4VlKGS{dXegd4Vve2m2aY\peJkhd2ZiND3PTHQh[W6mIH\1cJZme3S{YX70 Mn3JNlY{PTF|MkO=
MCF7 LTED MnXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUW5U4h4OjByIH7N NVzWNnJmPiCm NVy4UZQ6cW6lcnXhd4VlKGS{dXegd4Vve2m2aY\peJkhd2ZiND3PTHQh[W6mIH\1cJZme3S{YX70 M4r6UVI3OzVzM{Kz
ZR75 LTED M{DxZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHs[o8yODBibl2= NF\pOVE3KGR? MXjpcoNz\WG|ZXSg[JJ2\yC|ZX7zbZRqfmm2eTDv[kA1NU:KVDDhcoQh\nWudnXzeJJidnR? MUGyOlM2OTN{Mx?=
T74D LTED NFjie2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\TNVAxKG6P NULCPHZKPiCm M1LHNYlv[3KnYYPl[EBlenWpIIPlcpNqfGm4aYT5JI9nKDRvT1jUJIFv\CCodXz2[ZN1emGwdB?= NELaSGUzPjN3MUOyNy=>
TamR M3PoTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XCdlQxOCCwTR?= NFTEW5A3KGR? NEnFN|VqdmO{ZXHz[YQh\HK3ZzDz[Y5{cXSrdnn0fUBw\iB2LV;IWEBidmRiZoXseoV{fHKjboS= MojSNlY{PTF|MkO=
HCC1954 M2mwUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTBW4t{OC1zLkO1JO69VQ>? NWfFbpZrPSCm NYC3bm1X\W6qYX7j[ZMhfGinIHfyc5d1cCCrbnjpZol1cW:wIH;mJGFbTDh7M{G= M4DSSVI3ODl3NEe1
BT474c MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY[wMVEvOzVizszN NVvwelA6PSCm M2nhRoVvcGGwY3XzJJRp\SCpcn;3eIghcW6qaXLpeIlwdiCxZjDBXmQ5QTNz MnjENlYxQTV2N{W=
KPL4 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHYNE0yNjN3IN88US=> M1K0R|Uh\A>? NVHLU3M5\W6qYX7j[ZMhfGinIHfyc5d1cCCrbnjpZol1cW:wIH;mJGFbTDh7M{G= MUWyOlA6PTR5NR?=
SKBR3 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7jNE0yNjN3IN88US=> NUXmUYFzPSCm Mn[4[Y5p[W6lZYOgeIhmKGe{b4f0bEBqdmirYnn0bY9vKG:oIFHaSFg6OzF? NG\ZcmszPjB7NUS3OS=>
MR49C M3PSPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorKNE02KM7:TR?= M4Ky[VQ5KGh? MVXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MmjqNlUyPTFyMUK=
MR49F MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml[wNE02KM7:TR?= NXLtb3h2PDhiaB?= Ml7ubY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NV3XO|E3OjVzNUGwNVI>
NCI-H522 Mm\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPwcnJzUUN3ME2xNU4{KCkEsUKuO{kh|ryP M1myN|I1QTV5Nkiy
PC-9 NHvQeY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoS4TWM2OD17LkOgLOKyOS5{KTFOwG0> NV;qe5FjOjR7NUe2PFI>
NCI-H522 NUXOS5V6TnWwY4Tpc44hSXO|YYm= NUnSXHptOS93L{GwJO69VQ>? NWPCTZVzPC9{NDDo NVj5SmNXcW6lcnXhd4V{KEGNVDDwbI9{eGixconsZZRqd25? MnrBNlQ6PTd4OEK=
PC-9 Ml7nSpVv[3Srb36gRZN{[Xl? MmH6NU82NzFyIN88US=> NVXRRo5kPC9{NDDo MlLybY5kemWjc3XzJGFMXCCyaH;zdIhwenmuYYTpc44> NV7kOll1OjR7NUe2PFI>
HGC27 NVT4ZYFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTBwNES1JO69VQ>? NGHnNIszPDB6OEO4Ni=>
IM95m M{D1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPPOW5kUUN3ME2wMlUyKM7:TR?= MUeyOFA5QDN6Mh?=
AGS NGrtV|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fQW2lEPTB;MD61OVIh|ryP Ml\WNlQxQDh|OEK=
NCI-N87 MoHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTFwMEO3JO69VQ>? M13mOlI1ODh6M{iy
23132/87 M161O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTFwNkexJO69VQ>? Mn73NlQxQDh|OEK=
MKN1 M1TFRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTiTWM2OD1{LkSyNUDPxE1? M1zEd|I1ODh6M{iy
SNU-620 NH;ONG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTNwM{i0JO69VQ>? NGS3[5kzPDB6OEO4Ni=>
SNU-638 NV\NTHpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnZbZVWUUN3ME20MlUzOyEQvF2= M4[5UlI1ODh6M{iy
SNU-1 M3;rVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3ywRWlEPTB;NT6yOVgh|ryP M1r4RlI1ODh6M{iy
SNU-601 NET4c4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYOxSoloUUN3ME21Mlk{QCEQvF2= NUHlWmQ5OjRyOEizPFI>
SNU-668 NGHLUYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jwfGlEPTB;Nj6wNFMh|ryP Ml2zNlQxQDh|OEK=
HS746T Mmn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTrZ|hKSzVyPU[uNFg1KM7:TR?= NITMUXUzPDB6OEO4Ni=>
KATO III M{i3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlu3TWM2OD15LkK2O{DPxE1? MoLuNlQxQDh|OEK=
SNU-484 M1ryUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTdwM{myJO69VQ>? MWiyOFA5QDN6Mh?=
SNU-16 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrGTWM2OD1zMT6wPVch|ryP NIXxcJIzPDB6OEO4Ni=>
OCUM-1 M4Toe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXToO2RMUUN3ME2xOE42OTVizszN MX2yOFA5QDN6Mh?=
NUGC-3 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTJzLki3N{DPxE1? NXK0UYZjOjRyOEizPFI>
AZ521 M1H6PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTJ3LkS0PEDPxE1? MkXYNlQxQDh|OEK=
SNU-216 MoL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{f6TmlEPTB;M{Cg{txO MXKyOFA5QDN6Mh?=
NUGC-4 MlriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTNyIN88US=> MkjLNlQxQDh|OEK=
SNU-5 MnzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3HTWM2OD1|MDFOwG0> MUGyOFA5QDN6Mh?=
GTL-16 MnTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4qwV2lEPTB;M{Cg{txO NVXwcVFjOjRyOEizPFI>
MKN74 NYrzcXBYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLWdnFxUUN3ME2zNEDPxE1? MnzUNlQxQDh|OEK=
PAMC82 NX[xNmZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTQNYVpUUN3ME2zNEDPxE1? NIDDNFMzPDB6OEO4Ni=>
LNCaP MorOSpVv[3Srb36gRZN{[Xl? NXHVRnFQPSEQvF2= Mnq4NE0zPCCq NVnzNGVVcW6mdXPld{BCU1SVNEezJIFv\CCDS2TUN|A5KHCqb4PwbI9zgWyjdHnvckBqdiCjIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> NUm0VnpPOjN7Nk[2NlE>
C4-2  NVPy[5JHTnWwY4Tpc44hSXO|YYm= MV21JO69VQ>? MUiwMVI1KGh? NF\oTGJqdmS3Y3XzJGFMXFN2N{OgZY5lKEGNVGSzNFgheGixc4Doc5J6dGG2aX;uJIlvKGFidHnt[UBl\XCnbnTlcpQhdWGwbnXy NF7CcFQzOzl4Nk[yNS=>
LNCaP MXnGeY5kfGmxbjDBd5NigQ>? MXG1JO69VQ>? M3PJb|AuOjRiaB?= M{n3XIlvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kB1cGViZHnzeIFtKEGNVD3wZZRpf2G7IHLpc41iemuncoOgbY5kdHWmaX7nJHBTSVN2MDyg[WlHPEVuIETFMWJROSxibWTPVkwh[W6mIGC3NEBUPiCtaX7hd4UhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> Mn3vNlM6PjZ4MkG=
C4-2  Mn;GSpVv[3Srb36gRZN{[Xl? MVm1JO69VQ>? MU[wMVI1KGh? MWDpcohq[mm2czDwbI9{eGixconsZZRqd25ib3[geIhmKGSrc4ThcEBCU1RvcHH0bJdigSCkaX;tZZJs\XK|IHnuZ4x2\GmwZzDQVmFUPDBuIHXJSlRGNCB2RT3CVFEtKG2WT2KsJIFv\CCSN{CgV|Yhc2mwYYPlJIlvKGFidHnt[U1l\XCnbnTlcpQhdWGwbnXy M4\JPVI{QTZ4NkKx
LNCaP MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX6xMVExODByIH7N MW[wMVMh\A>? NH20cHZqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NUDLclVIOjN7Nk[2NlE>
C4-2  M3\0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjnNU0yODByMDDuUS=> NWTzRZg6OC1|IHS= MmTKbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NXjvSmNkOjN7Nk[2NlE>
LNCaP MnfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mom4NVAxNTVyMECgcm0> M1LCdFczKGh? NVXOe|ZPcW6lcnXhd4V{KHSqZTDmdoFkfGmxbjDv[kBk\WyuczD1coRmemexaX7nJINmdGxiZHXheIg> NYXWe3d5OjN7Nk[2NlE>
C4-2  M{fDTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LZdVExOC13MECwJI5O MmXaO|IhcA>? M3zR[Ylv[3KnYYPld{B1cGViZoLhZ5Rqd25ib3[gZ4VtdHNidX7k[ZJod2mwZzDj[YxtKGSnYYTo MYGyN|k3PjZ{MR?=
PC-3 MlTNSpVv[3Srb36gRZN{[Xl? MknQNE42NzFxMUCg{txO NYHVcJdJPDhiaB?= NWPQeJQ2\G:5boLl[5Vt[XSnczD0bIUheGixc4Doc5J6dGG2aX;uJI9nKGSxd37zeJJm[W1icHH0bJdigSCycn;0[YlveyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NIrRZnAzOzJ3OEe0NC=>
DU145  NF3GOWVHfW6ldHnvckBCe3OjeR?= NEO3dpMxNjVxMT:xNEDPxE1? MXy0PEBp MV7kc5dvemWpdXzheIV{KHSqZTDwbI9{eGixconsZZRqd25ib3[g[I94dnO2cnXhcUBx[XSqd3H5JJBzd3SnaX7zJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M4fiOlI{OjV6N{Sw
LNCaP NYroOJB2S2WubDDWbYFjcWyrdImgRZN{[Xl? MkjnNE0yODByIH7N NYf2SWl2OC12IHS= MXry[YR2[2WmIFzOR4FRKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7lduKh MVWyN|I2QDd2MB?=
PC-3  MVHGeY5kfGmxbjDBd5NigQ>? MmX6NVAh|ryP NELGVZoyOiCq NWHx[|lbcW6mdXPld{BifXSxcHjh[5k> MUKyN|I2QDd2MB?=

... Click to View More Cell Line Experimental Data

In vivo Oral dosing of AZD5363 (100, 300 mg/kg) to nude mice causes dose- and time-dependent reduction of PRAS40, GSK3β, and S6 phosphorylation in BT474c xenografts, reversible increases in blood glucose concentrations, and dose-dependent decreases in 2[18F]fluoro-2-deoxy-d-glucose (18F-FDG) uptake in U87-MG xenografts. Chronic oral dosing of AZD5363 (130, 200, and 300 mg/kg) causes dose-dependent growth inhibition of xenografts derived from various tumor types, including HER2+ breast cancer models that are resistant to trastuzumab. AZD5363 also significantly enhances the antitumor activity of docetaxel, lapatinib, and trastuzumab in breast cancer xenografts. [2]

Protocol

Kinase Assay:[1]
+ Expand

Caliper Off-Chip Incubation Mobility Shift assay:

The ability of AZD5363 and other compounds to inhibit the activity of AKT1, AKT2, and AKT3 is evaluated by the Caliper Off-Chip Incubation Mobility Shift assay. Active recombinant AKT1, AKT2, or AKT3 are incubated with a 5-FAM-labeled custom-synthesized peptide substrate together with increasing concentrations of inhibitor. Final reactions contained 1 to 3 nM AKT1, AKT2, or AKT3 enzymes; 1.5 mM peptide substrate; ATP at K m for each AKT isoform; 10 mM MgCl2, 4 mM DTT, 100 mM HEPES, and 0.015% Brij-35. The reactions are incubated at room temperature for 1 hour and stopped by the addition of buffer containing 100 mM HEPES, 0.015% Brij-35 solution, 0.1% coating reagent, 40 mM EDTA, and 5% DMSO. Plates are then analyzed using a Caliper LC3000, allowing for separation of peptide substrate and phosphorylated product by electrophoresis with subsequent detection and quantification of laser induced fluorescence.
Cell Research: [2]
+ Expand
  • Cell lines: 182 solid and hematologic tumor cell lines
  • Concentrations: ~30 μM
  • Incubation Time: 72 hours
  • Method: Cell proliferation assay is determined by 2 methods, MTS and Sytox Green. Briefly, cells are seeded in 96-well plates and incubated overnight at 37 ℃, 5% CO2. Cells are then exposed to concentrations of AZD5363 ranging from 30 to 0.003μM for 72 hours. For the MTS endpoint, cell proliferation is measured by the CellTiter AQueous Non-Radioactive Cell Proliferation Assay reagent in accordance with the manufacturer's protocol. For the Sytox Green endpoint, Sytox Green nucleic acid dye diluted in TBS-EDTA buffer is added to cells (final concentration of 0.13 μM) and the number of dead cells detected using an Acumen Explorer. Cells are then permeabilized by the addition of saponin (0.03% final concentration, diluted in TBS-EDTA buffer), incubated overnight and a total cell count measured. Predose measurements are made for both MTS and Sytox Green endpoints, and concentration needed to reduce the growth of treated cells to half that of untreated cells values are determined using absorbance readings (MTS) or live cell counts.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Female nude mice and male SCID mice with BT474c, U87MG, KPL-4, HCC-1187 xenografts.
  • Formulation: In 10% DMSO 25% w/v Kleptose HPB
  • Dosages: 130 mg/Kg - 300 mg/Kg
  • Administration: p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 86 mg/mL (200.5 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
1% CMC Na
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 428.92
Formula

C21H25ClN6O2

CAS No. 1143532-39-1
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02451956 Recruiting Advanced Gastric Cancer Samsung Medical Center January 7 2015 Phase 2
NCT01625286 Active not recruiting Advanced or Metastatic Breast Cancer|ER+ve Advanced or Metastatic Breast Cancer AstraZeneca October 3 2012 Phase 1|Phase 2
NCT02121639 Recruiting Prostate Cancer University Hospital Southampton NHS Foundation Trust|AstraZeneca|Cancer Research UK January 29 2014 Phase 1|Phase 2
NCT02525068 Recruiting Adenocarcinoma of the Prostate Institute of Cancer Research United Kingdom|Royal Marsden NHS Foundation Trust December 2014 Phase 2
NCT02423603 Active not recruiting Metastatic Breast Cancer Queen Mary University of London|AstraZeneca|Cancer Research UK May 2014 Phase 2
NCT02338622 Unknown status Advanced Cancer Royal Marsden NHS Foundation Trust|Institute of Cancer Research United Kingdom|AstraZeneca March 2014 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

Related Akt Products

Tags: buy AZD5363 | AZD5363 supplier | purchase AZD5363 | AZD5363 cost | AZD5363 manufacturer | order AZD5363 | AZD5363 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID